Navigation Links
AACR news: Rigosertib Phase 1 results lead to disease-focused Phase 2 development

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ.

Overall, 48 patients were included in the Phase I trial with oral rigosertib, and 7 remained on study for at least six months. Six head and neck cancer patients included in this study had failed platinum-based therapies, and 2 of these patients showed a response to Rigosertib one with the disappearance of lung metastasis and another with greater than 50 percent decrease of liver metastasis. These 2 patients have received oral rigosertib treatment for 98 and 48 weeks.

"The results from the head and neck cancer patients are interesting, revealing that the drug worked in a subset of patients," says Antonio Jimeno, MD, PhD, investigator at the University of Colorado Cancer Center and director of the university's Head and Neck Cancer Medical Oncology Program. "To learn more about the relationship between response and genetic make-up of the tumor, we've been investigating molecular correlates in a surrogate Phase 2 trial in patient-derived animal models of head and neck cancer."

As highlighted in the AACR presentation, genetic analysis of tumor samples from the Phase 1 trial and continuing genetic analysis of animal models, performed at both the Colorado Molecular Correlates Laboratory (CMOCO) and Dr. Jimeno's research laboratory, detected several potential biomarkers, including the genes PIK3CA and PTEN, which are both members of the signaling pathway targeted by the drug. Whole-exome sequencing of patient samples also revealed what Jimeno calls, "a short list of core alterations in genes for further exploration as predictive biomarkers."

"These promising results from human trial combined with relevant animal models established in our laboratories are helping us learn more about this drug and its mechanism of action. Based on these studies, we are initiating an 80-patient, multi-institutional Phase 2 trial," says Jimeno. In this trial, tissue samples from patients will be analyzed by sequencing and using other genomic tools to fully explore the predictive capability of these candidate biomarkers.

"We have seen meaningful activity in a subset of patients in the Phase I trial and we confirmed this in the surrogate animal model," Jimeno says. "The hope is that broad genetic analysis will help identify biomarkers for accurately matching the drug with the right patients in the future."

"It's an exciting time for an exciting drug," Jimeno says.


Contact: Garth Sundem
University of Colorado Denver

Related medicine news :

1. Good news: Migraines hurt your head but not your brain
2. Grape News: Global Wine Manufacturing Industry Market Research Report from IBISWorld has Been Updated
3. Actos Lawsuit News: Bernstein Liebhard LLP Notes Latest Scheduling Order in Actos Bladder Cancer Litigation
4. Zoloft Lawsuit News: Bernstein Liebhard LLP Notes New Pretrial Order in Federal Zoloft Litigation Establishing Tentative Date for First Bellwether Trial
5. MinuteHound News: Top Three Ways To Save Money With Biometric Time and Attendance Solutions
6. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conferences in Federal Transvaginal Mesh Litigations
7. Da Vinci Robotic Surgery Lawsuit News: Ohio Law Firm Investigates Da Vinci Robotic Surgery Complications as Settlement is Reached in Louisiana Da Vinci Robot Lawsuit
8. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
9. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
10. ALS patients differ on treatment choices in later phases of disease
11. Reach2HD, a Phase II study in Huntingtons disease, launched
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Next IT Healthcare, the leader in patient ... year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of ... the category of Digital Solutions for its innovative, industry-leading product, Alme Health Coach. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Lutronic, a ... of Clarity, the latest addition to the devices for sale in the United States. ... nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... SACC-GA and SACC-USA through membership and leadership since 2008. Gary Bruce, President ... SACC-USA . Gary has spent a significant amount of time in Sweden ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., ... largest order to date. , The order will be from the China Disabled ... Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, announced ... data collection of vital signs. Photo - ... ... ... ...
(Date:12/1/2015)... , Dec. 1, 2015 Ampio Pharmaceuticals, ... York Stock Exchange has established January 5, 2016 as the ... stockholders of the shares of Common Stock of Aytu ... share of Aytu common stock for every five (5) ... record date, December 1, 2015. The distribution date will be ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... International Breast Cancer Study Group (IBCSG, Bern ... ) to be part of a state of the ... cancer drug.  --> --> ... cancer being treated with anti-hormonal therapy in combination with palbociclib, ...
Breaking Medicine Technology: